Emergent BioSolutions (EBS) FCF Margin Growth (3y) (2014 - 2026)
Emergent BioSolutions (EBS) FCF Margin Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 213.00 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2,102.00 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 180.00 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1,592.00 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -291.00 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -2,476.00 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1,604.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 6,060.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,060.00 |
| Mar 31, 2026 | 9,355.00 |
| Dec 31, 2025 | -79.00 |
| Sep 30, 2025 | 4,351.00 |
| Jun 30, 2025 | 9,312.00 |
| Mar 31, 2025 | 1,614.00 |
| Dec 31, 2024 | -8,395.00 |
| Sep 30, 2024 | 3,344.00 |
| Jun 30, 2024 | 7,846.00 |
| Mar 31, 2024 | -1,467.00 |
| Dec 31, 2023 | -4,758.00 |
| Sep 30, 2023 | -1,120.00 |
| Jun 30, 2023 | -6,323.00 |
| Mar 31, 2023 | -13,419.00 |
| Dec 31, 2022 | 862.00 |
| Sep 30, 2022 | -3,657.00 |
| Jun 30, 2022 | 674.00 |
| Mar 31, 2022 | -7,406.00 |
| Dec 31, 2021 | 8,977.00 |
| Sep 30, 2021 | -6,824.00 |